Xenon Pharmaceuticals (XENE) Enterprise Value (2013 - 2026)
Xenon Pharmaceuticals (XENE) reported Enterprise Value of -$1.1 billion for Q1 2026, down 99.18% year-over-year from -$133.4 billion in Q1 2025, and down 99.45% quarter-over-quarter from -$548.9 million in Q4 2025.
Xenon Pharmaceuticals (XENE) Enterprise Value (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has 14 years of Enterprise Value data on file, last reported at -$1.1 billion in Q1 2026.
- Enterprise Value for Q1 2026 came in at -$1.1 billion, down 99.18% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.1 billion (down 99.18% YoY), and the FY2025 annual result was -$548.9 million, up 12.45% from the prior year.
- Enterprise Value declined to -$1.1 billion in Q1 2026 per XENE's latest filing, from -$548.9 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$487.5 million in Q2 2025 and troughed at -$1.1 billion in Q1 2026.
- A 5-year average of -$652.0 million and a median of -$626.9 million in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2025: Enterprise Value plunged 202.56% in 2022, then surged 32.43% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$592.1 million in 2022, then fell by 7.77% to -$638.1 million in 2023, then climbed by 1.75% to -$626.9 million in 2024, then grew by 12.45% to -$548.9 million in 2025, then slumped by 99.45% to -$1.1 billion in 2026.
- Business Quant data shows XENE's Enterprise Value at -$1.1 billion in Q1 2026, -$548.9 million in Q4 2025, and -$913.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -584.73 Mn |
| 10 | Xenon Pharmaceuticals | 4.61 Bn | 4.61 Bn | - | -1.09 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.09 Bn |
| Dec 31, 2025 | -548.89 Mn |
| Sep 30, 2025 | -913.01 Mn |
| Jun 30, 2025 | -487.55 Mn |
| Mar 31, 2025 | -549.63 Mn |
| Dec 31, 2024 | -626.91 Mn |
| Sep 30, 2024 | -654.02 Mn |
| Jun 30, 2024 | -721.54 Mn |
| Mar 31, 2024 | -699.60 Mn |
| Dec 31, 2023 | -638.08 Mn |
| Sep 30, 2023 | -526.67 Mn |
| Jun 30, 2023 | -539.60 Mn |
| Mar 31, 2023 | -527.04 Mn |
| Dec 31, 2022 | -592.09 Mn |
| Sep 30, 2022 | -638.19 Mn |
| Jun 30, 2022 | -788.24 Mn |
| Mar 31, 2022 | -537.94 Mn |
| Dec 31, 2021 | -551.77 Mn |
| Sep 30, 2021 | -249.63 Mn |
| Jun 30, 2021 | -260.52 Mn |